Literature DB >> 23649425

Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

Sook Wah Yee1, Anh Nguyet Nguyen, Chaline Brown, Radojka M Savic, Youcai Zhang, Richard A Castro, Cheryl D Cropp, Ji Ha Choi, Diment Singh, Harunobu Tahara, Sophie L Stocker, Yong Huang, Claire M Brett, Kathleen M Giacomini.   

Abstract

Organic anion transporter 3 (OAT3, SLC22A8), a transporter expressed on the basolateral membrane of the proximal tubule, plays a critical role in the renal excretion of organic anions including many therapeutic drugs. The goal of this study was to evaluate the in vivo effects of the OAT3-Ile305Phe variant (rs11568482), present at 3.5% allele frequency in Asians, on drug disposition with a focus on cefotaxime, a cephalosporin antibiotic. In HEK293-Flp-In cells, the OAT3-Ile305Phe variant had a lower maximum cefotaxime transport activity, Vmax , [159 ± 3 nmol*(mg protein)(-1) /min (mean ± SD)] compared with the reference OAT3 [305 ± 28 nmol*(mg protein)(-1) /min, (mean ± SD), p < 0.01], whereas the Michaelis-Menten constant values (Km ) did not differ. In healthy volunteers, we found volunteers that were heterozygous for the Ile305Phe variant and had a significantly lower cefotaxime renal clearance (CLR ; mean ± SD: 84.8 ± 32.1 mL/min, n = 5) compared with volunteers that were homozygous for the reference allele (158 ± 44.1 mL/min, n = 10; p = 0.006). Furthermore, the net secretory component of cefotaxime renal clearance (CLsec ) was reduced in volunteers heterozygous for the variant allele [33.3 ± 31.8 mL/min (mean ± SD)] compared with volunteers homozygous for the OAT3 reference allele [97.0 ± 42.2 mL/min (mean ± SD), p = 0.01]. In summary, our study suggests that a low-frequency reduced-function polymorphism of OAT3 associates with reduced cefotaxime CLR and CL(sec) .
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  OAT3; cefotaxime; organic anion transporter; pharmacogenomic; pharmacokinetics; polymorphisms; renal clearance; tubular secretion

Mesh:

Substances:

Year:  2013        PMID: 23649425      PMCID: PMC4151246          DOI: 10.1002/jps.23581

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  37 in total

1.  Pharmacokinetics of cefotaxime in normal human volunteers.

Authors:  F Esmieu; J Guibert; H C Rosenkilde; I Ho; A Le Go
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

2.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

3.  The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.

Authors:  R M Ings; D S Reeves; L O White; R P Bax; M J Bywater; H A Holt
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

4.  The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion.

Authors:  C A Verhagen; H Mattie; E Van Strijen
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

Review 5.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.

Authors:  R M Ings; J P Fillastre; M Godin; A Leroy; G Humbert
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

7.  Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients.

Authors:  S Urien; N Laurent; J Barre; M Druguet; M Bouvier D'yvoire; P Maire
Journal:  Eur J Clin Pharmacol       Date:  2004-02-07       Impact factor: 2.953

8.  Effect of probenecid on the pharmacokinetics of cefotaxime in sheep.

Authors:  V H Guerrini; L J Filippich; P B English; G R Cao; D W Bourne
Journal:  J Vet Pharmacol Ther       Date:  1985-03       Impact factor: 1.786

9.  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.

Authors:  U Jaehde; F Sörgel; A Reiter; G Sigl; K G Naber; W Schunack
Journal:  Clin Pharmacol Ther       Date:  1995-11       Impact factor: 6.875

10.  Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.

Authors:  T B Vree; M van den Biggelaar-Martea; C P Verwey-van Wissen
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

View more
  19 in total

Review 1.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

Review 2.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 3.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

Review 4.  Pharmacogenomics of COVID-19 therapies.

Authors:  Takuto Takahashi; Jasmine A Luzum; Melanie R Nicol; Pamala A Jacobson
Journal:  NPJ Genom Med       Date:  2020-08-18       Impact factor: 8.617

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 6.  Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.

Authors:  Sook Wah Yee; Deanna J Brackman; Elizabeth A Ennis; Yuichi Sugiyama; Landry K Kamdem; Rebecca Blanchard; Aleksandra Galetin; Lei Zhang; Kathleen M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2018-05-31       Impact factor: 6.875

Review 7.  What do drug transporters really do?

Authors:  Sanjay K Nigam
Journal:  Nat Rev Drug Discov       Date:  2014-12-05       Impact factor: 84.694

8.  Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity.

Authors:  Ling Zou; Adrian Stecula; Anshul Gupta; Bhagwat Prasad; Huan-Chieh Chien; Sook Wah Yee; Li Wang; Jashvant D Unadkat; Simone H Stahl; Katherine S Fenner; Kathleen M Giacomini
Journal:  Mol Pharmacol       Date:  2018-05-02       Impact factor: 4.436

9.  A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

Authors:  Stéphanie Leroux; Jean-Michel Roué; Jean-Bernard Gouyon; Valérie Biran; Hao Zheng; Wei Zhao; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

10.  Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.

Authors:  S W Yee; M M Giacomini; C-H Hsueh; D Weitz; X Liang; S Goswami; J M Kinchen; A Coelho; A A Zur; K Mertsch; W Brian; D L Kroetz; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2016-09-20       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.